JPRN-UMIN000004034Completed未知
A dose-comparative study of ursodeoxycholic acid in nonalcoholic steatohepatitis (NASH) with glucose metabolism disorder and dyslipidemia - A dose-comparative study of ursodeoxycholic acid in nonalcoholic steatohepatitis (NASH) with glucose metabolism disorder and dyslipidemia
Division of Gastroenterology, Saiseikai Suita Hospital0 sites60 target enrollmentStarted: August 13, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)During the pretreatment period, the patient treated with a choleretic drug, a glycyrrhizin-combination drug, an immunotherapeutic drug, an adrenal corticoid, a liver hydrolysate, an enhancement drug of liver function, a Saiko-prescription, a bile-acid sequestrant, a phlebotomy or a folk medicine which may affect the target disorder. 2)During the pretreatment period, the patient with a discontinuation, an alternation of dose or dosage regimen, or a new additional dosage of the following drug: a) Antidiabetic drugs: an insulin preparation, a SU drug, a biguanide, an alpha-gluosidase inhibitor, a drug for postprandial hyperglycemia of the early phase, a DPP4 inhibitor, b) Anti-oxidants: a vitamin E preparation, a N-Accetyl-Cysteine preparation, c) Hypolipidemic drugs: a fibrate, a HMG-CoA reductase inhibitor, a probucol, an EPA capsule, an intestinal cholesterol-transporter inhibitor, d) Anti-hypertensive drugs: an angiotensin II receptor type-1 antagonist (ARB). 3)The patient with type1 or 2 of the Matteoni classification from biopsy examination. 4)The patient with cirrhosis diagnosed from biopsy examination (diagnosis as F4 from liver biopsy). 5)The patient in cancer therapy. 6)The patient with complete biliary atresia. 7)The patient in therapy of fulminant hepatitis. 8)The patient during pregnancy, feeding, intimation of pregnancy or intended pregnancy. 9)The patient with history of hypersensitivity to test drug 10)The patient who was diagnosed as an inappropriate one by the researcher.
Investigators
Similar Trials
Recruiting
Not Applicable
The efficacy of Ursodeoxycholic on faster improvement of patients with psoriasisPsoriasis.psoriasis vulgarisIRCT2017092536415N1Tehran University of Medical Sciences30
Recruiting
Phase 3
The efficacy of ursodeoxycholic acid therapy in delay cholecystectomyAcute cholecystitisIRCT20210309050650N1Zanjan University of Medical Sciences60
Not yet recruiting
Phase 3
Effect of ursodeoxycholic acid in reducing hospitalization for phototherapyIRCT20190604043813N4Shiraz University of Medical Sciences148
Recruiting
Phase 3
Investigating the Effect of Ursodeoxycholic acid and Phototherapy against Phototherapy alone in Reducing the Plasma Level of Bilirubin in InfantsHyperbilirubinemia.Other disorders of bilirubin metabolismE80.6IRCT20231220060483N1Shahid Beheshti University of Medical Sciences200
Recruiting
Phase 3
Comparison of the therapeutic effect of Ursodeoxycholic acid and Synbiotic versus isolated phototherapy on indirect hyperbilirubinemia.Indirect Hyperbilirubinemia (Neonatal jaundice).Neonatal jaundice due to excessive hemolysis, unspecifiedIRCT20181006041252N9Sabzevar University of Medical Sciences120